Vaccination in paediatric, adolescent, and transitional-age rheumatic diseases: A systematic review.

IF 1.9 4区医学 Q3 RHEUMATOLOGY

Modern Rheumatology Pub Date : 2025-07-25 DOI:10.1093/mr/roaf069

Takuma Ohnishi, Hiroyuki Wakiguchi, Shingo Ishimori, Naohiro Itoh, Masato Yashiro, Susumu Yamazaki, Ikuo Okafuji, Yoshiyuki Ohtomo, Ichiro Kobayashi

{"title":"Vaccination in paediatric, adolescent, and transitional-age rheumatic diseases: A systematic review.","authors":"Takuma Ohnishi, Hiroyuki Wakiguchi, Shingo Ishimori, Naohiro Itoh, Masato Yashiro, Susumu Yamazaki, Ikuo Okafuji, Yoshiyuki Ohtomo, Ichiro Kobayashi","doi":"10.1093/mr/roaf069","DOIUrl":null,"url":null,"abstract":"Objective: This systematic review evaluated the efficacy and safety of vaccination in patients with paediatric, adolescent, and transitional-age rheumatic diseases as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement.Methods: An independent investigator systematically searched PubMed to identify relevant studies published by September 2022. The search results were divided into vaccines or toxoids for diphtheria, pertussis, tetanus, pneumococcus, influenza virus, hepatitis A virus, hepatitis B virus, human papillomavirus, poliovirus, measles virus, mumps virus, rubella virus, varicella zoster virus, and tuberculosis.Results: A meta-analysis was not feasible due to the lack of randomized controlled trials with standardized patient backgrounds and conditions. Non-live vaccines are generally immunogenic and safe for patients with rheumatic diseases. In contrast, live attenuated vaccines should usually be withheld in patients on immunosuppressants, corticosteroids, biologics, or Janus kinase inhibitors. However, for necessary immunizations against measles, rubella, mumps, or varicella, live attenuated vaccines may be considered for patients receiving low-dose corticosteroids, methotrexate, or tumour necrosis factor inhibitors.Conclusion: This review highlights the significant gap in evidence for paediatric populations compared with adults, particularly concerning new biological therapies and Janus kinase inhibitors. Further evidence is needed regarding vaccination in paediatric patients with rheumatic diseases.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roaf069","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This systematic review evaluated the efficacy and safety of vaccination in patients with paediatric, adolescent, and transitional-age rheumatic diseases as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement.

Methods: An independent investigator systematically searched PubMed to identify relevant studies published by September 2022. The search results were divided into vaccines or toxoids for diphtheria, pertussis, tetanus, pneumococcus, influenza virus, hepatitis A virus, hepatitis B virus, human papillomavirus, poliovirus, measles virus, mumps virus, rubella virus, varicella zoster virus, and tuberculosis.

Results: A meta-analysis was not feasible due to the lack of randomized controlled trials with standardized patient backgrounds and conditions. Non-live vaccines are generally immunogenic and safe for patients with rheumatic diseases. In contrast, live attenuated vaccines should usually be withheld in patients on immunosuppressants, corticosteroids, biologics, or Janus kinase inhibitors. However, for necessary immunizations against measles, rubella, mumps, or varicella, live attenuated vaccines may be considered for patients receiving low-dose corticosteroids, methotrexate, or tumour necrosis factor inhibitors.

Conclusion: This review highlights the significant gap in evidence for paediatric populations compared with adults, particularly concerning new biological therapies and Janus kinase inhibitors. Further evidence is needed regarding vaccination in paediatric patients with rheumatic diseases.

查看原文本刊更多论文

儿童、青少年和过渡年龄风湿病的疫苗接种：系统综述。

目的：本系统综述根据系统评价和荟萃分析（PRISMA） 2020声明的首选报告项目评估了儿童、青少年和过渡年龄风湿病患者接种疫苗的有效性和安全性。方法：由独立研究者系统检索PubMed，找出2022年9月前发表的相关研究。搜索结果分为白喉、百日咳、破伤风、肺炎球菌、流感病毒、甲型肝炎病毒、乙型肝炎病毒、人乳头瘤病毒、脊髓灰质炎病毒、麻疹病毒、腮腺炎病毒、风疹病毒、水痘带状疱疹病毒和结核病的疫苗或类毒素。结果：由于缺乏标准化患者背景和条件的随机对照试验，荟萃分析是不可行的。非活疫苗通常具有免疫原性，对风湿病患者是安全的。相反，在使用免疫抑制剂、皮质类固醇、生物制剂或Janus激酶抑制剂的患者中，通常不应使用减毒活疫苗。然而，对于麻疹、风疹、腮腺炎或水痘的必要免疫接种，可考虑对接受低剂量皮质类固醇、甲氨蝶呤或肿瘤坏死因子抑制剂治疗的患者接种减毒活疫苗。结论：本综述强调了与成人相比，儿科人群的证据存在显著差距，特别是在新的生物疗法和Janus激酶抑制剂方面。关于风湿病患儿的疫苗接种，需要进一步的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Modern Rheumatology RHEUMATOLOGY-

CiteScore

4.90

自引率

9.10%

发文量

146

审稿时长

1.5 months

期刊介绍： Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions